李奇渊 - 厦门大学

个人简介

学习经历： 1996~2000 华东理工大学本科； 2000~2003 厦门大学细胞生物学硕士； 2004~2006 丹麦科技大学生物信息学硕士； 2006~2010 丹麦科技大学系统生物学博士。工作经历： 2010.03~2012.03 哈佛癌症中心博士后； 2012.05~2017.11 厦门大学医学院副教授； 2017.11~至今厦门大学医学院教授； 2015~至今挂职担任厦门大学附属第一医院儿内科科研副主任，开展儿科遗传性缺陷筛查和科研支撑工作； 2016~至今挂职担任卫计委健康医疗大数据管理中心主任。负责建立人口健康大数据应用开放平台，支持儿科智能化研究。

研究领域

主要从事针对肿瘤基因组的转化医学研究，运用统计学模型从遗传多态性，体细胞变异，表观基因组学和基因表达等多组学数据中寻找与肿瘤分型，预后，靶向治疗敏感性等临床特征有关的决定因子并解释其调控机制；在此基础上建立基于多组学关联的复杂网络模型，应用人工智能方法发现新的肿瘤驱动基因。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Li Q, Stram A, Chen C, Kar S, Gayther S, Pharoah P, Haiman C, Stranger B, Kraft P, Freedman ML. Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Hum Mol Genet. 2014 Oct 1;23(19):5294-302. Seo JH, Li Q, Fatima A, Eklund A, Szallasi Z, Polyak K, Richardson AL, Freedman ML. Deconvoluting complex tissues for expression quantitative trait locus-based analyses.Philos Trans R Soc Lond B Biol Sci. 2013 May 6;368(1620):20120363. doi: 10.1098/rstb.2012.0363. Li Q, Seo JH, Stranger B, McKenna A, Pe'er I, LaFramboise T, Brown, M, Tyekucheva S, Freedman ML. Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci. Cell 2013, 152(3):633 Li Q, Birkbak NJ, Gyorffy B, Szallasi1 Z and Aron CE: Jetset: the optimal microarray probe set to represent a gene. BMC Bioinformatics 2011, 12:474 Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kain B, Sotiriou C, Symmans W. F, Pusztai L, Brunak S, Richardson AL, Szallasi Z: Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response BMC Bioinformatics. BMC Bioinformatics 2011, 12:310 Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z, Downward J: Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 2009, 106(21):8671-8676. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C: Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011, 71(10):3447-3452. Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL, Szallasi Z, Swanton C: Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS One 2010, 5(12):e15031. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C: Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010, 11(4):358-365. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC: Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010, 16(2):214-218. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28(7):1145-1153. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123(3):725-731. Li Q, Jorgensen FS, Oprea T, Brunak S, Taboureau O: hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol Pharm 2008, 5(1):117-127.